Surrozen focuses on ophthalmology programs, raising $175 million to advance treatments while discontinuing SZN-043 for alcohol-associated hepatitis. Surrozen, Inc. has announced a strategic shift to ...
NEW YORK and CLEVELAND, March 14, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced three internally developed investigational preclinical gene therapy product ...
BioWorld - Sunday, April 13, 2025 Breaking News: Explore BioWorld’s comprehensive infographics collection See today's BioWorld Science Home » Genflow announces ophthalmology program based on SIRT6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback